Prolytix is a leading analytical CRO with 30+ years of protein chemistry experience in plasma-based protein therapies, monoclonal and polyclonal antibodies, recombinant proteins, cell and gene therapies, and vaccines and viral vectors, from discovery through commercial GMP release and stability. Prolytix also develops custom collection tubes, vials, other devices for nonclinical and clinical research and manufactures standard and custom plasma-derived coagulation proteins, antibodies, and factor deficient plasma research reagents.
Recent Posts
- Edgewater Capital Partners Acquires NeoGraf Solutions, LLC
- Evantic, a Portfolio Company of Edgewater Capital Partners, Acquires Vertec Polymers, Inc.
- SK Capital Partners and Edgewater Capital Partners Close Acquisition of Crystals Business from Saint-Gobain
- Edgewater Capital Partners Completes Sale of ChemQuest Chemicals to Seatex
- SK Capital Partners and Edgewater Capital Partners Announce Acquisition of Saint-Gobain’s Crystals Business
- Edgewater Capital Invests in GL CHEMTEC
- Naprotek, a Portfolio Company of Edgewater Capital Partners, Acquires MicroFab
- Edgewater Capital Partners Acquires AmeriWater
- Naprotek, a Portfolio Company of Edgewater Capital Partners, Acquires NexLogic
- Altamira MS Holdings, a Portfolio Company of Edgewater Capital Partners, Acquires Precision Fluorocarbon, LLC